STAAR Surgical Company (NASDAQ: STAA) postponed its special meeting of stockholders to December 3, 2025, setting a new record date of October 24, 2025. The meeting will allow shareholders who hold shares on that date to vote on the company’s merger agreement with Alcon (NYSE: ALC).
The merger, announced on August 5, 2025, sees Alcon acquire STAAR for $28 per share in cash, valuing the deal at approximately $1.5 billion. The postponement follows a prior adjournment to November 6, 2025, and gives shareholders additional time to review the terms amid significant opposition from major shareholders, including Broadwood Partners (27.5 %) and proxy advisory firms ISS, Glass Lewis, and Egan‑Jones, who have called for board changes and questioned the price.
The transaction is subject to regulatory approval; the Hart‑Scott‑Rodino waiting period expired on September 30, 2025. STAAR has engaged Innisfree M&A as its proxy solicitor to assist shareholders with voting.
STAAR’s management maintains that the merger remains on track, but the extended timeline provides a buffer for any market or regulatory developments that could affect the completion of the deal.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.